Drugs / BT086
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01420744 | Aug 2011 → Feb 2015 | — | Biotest | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT086 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01420744 ↗ |
| Known as | trimodulin | “The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing ~ 23% immunoglobulin (Ig) M, ~ 21% IgA, and ~ 56% IgG as add-on therapy for...” PMID 29632995 ↗ Apr 2018 |
| Modality | Protein / enzyme biologic | “The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing ~ 23% immunoglobulin (Ig) M, ~ 21% IgA, and ~ 56% IgG as add-on therapy for...” PMID 29632995 ↗ Apr 2018 |
| Route | Intravenous | “BT086 will be administered per intravenous infusion (IV).” NCT01420744 ↗ |